Financhill
Sell
33

GPCR Quote, Financials, Valuation and Earnings

Last price:
$21.05
Seasonality move :
47.59%
Day range:
$20.85 - $22.25
52-week range:
$19.39 - $62.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.44x
Volume:
325.3K
Avg. volume:
816.6K
1-year change:
-38.18%
Market cap:
$1.2B
Revenue:
--
EPS (TTM):
-$2.35

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
GPCR
Structure Therapeutics
-- -$0.17 -- -59.43% $80.15
ALT
Altimmune
-- -$0.34 -88.8% -7.65% $22.38
AMGN
Amgen
$8.9B $5.08 8.14% 257.4% $315.95
LLY
Eli Lilly and
$13.4B $5.07 45.75% 89.16% $1,006.63
TERN
Terns Pharmaceuticals
-- -$0.30 -- -7.38% $19.06
VKTX
Viking Therapeutics
-- -$0.27 -- -21.87% $99.29
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
GPCR
Structure Therapeutics
$21.79 $80.15 $1.2B -- $0.00 0% --
ALT
Altimmune
$5.97 $22.38 $459.8M -- $0.00 0% 21,196.69x
AMGN
Amgen
$317.17 $315.95 $170.4B 42.01x $2.38 2.88% 5.12x
LLY
Eli Lilly and
$824.76 $1,006.63 $740.8B 70.43x $1.50 0.66% 16.55x
TERN
Terns Pharmaceuticals
$3.25 $19.06 $276.1M -- $0.00 0% --
VKTX
Viking Therapeutics
$29.83 $99.29 $3.3B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
GPCR
Structure Therapeutics
-- 1.212 -- --
ALT
Altimmune
-- 3.397 -- 12.90x
AMGN
Amgen
91.09% 0.434 43.85% 0.84x
LLY
Eli Lilly and
70.33% 0.371 5.05% 0.59x
TERN
Terns Pharmaceuticals
-- 2.694 -- --
VKTX
Viking Therapeutics
-- -1.225 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
GPCR
Structure Therapeutics
-- -$47.1M -- -- -- -$36.5M
ALT
Altimmune
-- -$24.9M -61.21% -61.21% -463580% -$18.3M
AMGN
Amgen
$6B $2.3B 5.97% 66.87% 16.83% $4.4B
LLY
Eli Lilly and
$11.1B $5.8B 25.09% 80.24% 38.89% $726.6M
TERN
Terns Pharmaceuticals
-- -$24.9M -- -- -- -$16.5M
VKTX
Viking Therapeutics
-- -$46.2M -- -- -- -$31.2M

Structure Therapeutics vs. Competitors

  • Which has Higher Returns GPCR or ALT?

    Altimmune has a net margin of -- compared to Structure Therapeutics's net margin of -463600%. Structure Therapeutics's return on equity of -- beat Altimmune's return on equity of -61.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    GPCR
    Structure Therapeutics
    -- -$0.64 --
    ALT
    Altimmune
    -- -$0.33 $123.5M
  • What do Analysts Say About GPCR or ALT?

    Structure Therapeutics has a consensus price target of $80.15, signalling upside risk potential of 267.85%. On the other hand Altimmune has an analysts' consensus of $22.38 which suggests that it could grow by 274.79%. Given that Altimmune has higher upside potential than Structure Therapeutics, analysts believe Altimmune is more attractive than Structure Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    GPCR
    Structure Therapeutics
    7 0 0
    ALT
    Altimmune
    5 2 0
  • Is GPCR or ALT More Risky?

    Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Altimmune has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.083%.

  • Which is a Better Dividend Stock GPCR or ALT?

    Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Structure Therapeutics pays -- of its earnings as a dividend. Altimmune pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GPCR or ALT?

    Structure Therapeutics quarterly revenues are --, which are smaller than Altimmune quarterly revenues of $5K. Structure Therapeutics's net income of -$36.5M is lower than Altimmune's net income of -$23.2M. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Altimmune's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus 21,196.69x for Altimmune. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GPCR
    Structure Therapeutics
    -- -- -- -$36.5M
    ALT
    Altimmune
    21,196.69x -- $5K -$23.2M
  • Which has Higher Returns GPCR or AMGN?

    Amgen has a net margin of -- compared to Structure Therapeutics's net margin of 6.9%. Structure Therapeutics's return on equity of -- beat Amgen's return on equity of 66.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    GPCR
    Structure Therapeutics
    -- -$0.64 --
    AMGN
    Amgen
    65.75% $1.16 $66B
  • What do Analysts Say About GPCR or AMGN?

    Structure Therapeutics has a consensus price target of $80.15, signalling upside risk potential of 267.85%. On the other hand Amgen has an analysts' consensus of $315.95 which suggests that it could fall by -0.39%. Given that Structure Therapeutics has higher upside potential than Amgen, analysts believe Structure Therapeutics is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    GPCR
    Structure Therapeutics
    7 0 0
    AMGN
    Amgen
    9 14 2
  • Is GPCR or AMGN More Risky?

    Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amgen has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.288%.

  • Which is a Better Dividend Stock GPCR or AMGN?

    Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 2.88% to investors and pays a quarterly dividend of $2.38 per share. Structure Therapeutics pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

  • Which has Better Financial Ratios GPCR or AMGN?

    Structure Therapeutics quarterly revenues are --, which are smaller than Amgen quarterly revenues of $9.1B. Structure Therapeutics's net income of -$36.5M is lower than Amgen's net income of $627M. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Amgen's PE ratio is 42.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus 5.12x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GPCR
    Structure Therapeutics
    -- -- -- -$36.5M
    AMGN
    Amgen
    5.12x 42.01x $9.1B $627M
  • Which has Higher Returns GPCR or LLY?

    Eli Lilly and has a net margin of -- compared to Structure Therapeutics's net margin of 32.59%. Structure Therapeutics's return on equity of -- beat Eli Lilly and's return on equity of 80.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    GPCR
    Structure Therapeutics
    -- -$0.64 --
    LLY
    Eli Lilly and
    82.24% $4.88 $47.9B
  • What do Analysts Say About GPCR or LLY?

    Structure Therapeutics has a consensus price target of $80.15, signalling upside risk potential of 267.85%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 22.05%. Given that Structure Therapeutics has higher upside potential than Eli Lilly and, analysts believe Structure Therapeutics is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    GPCR
    Structure Therapeutics
    7 0 0
    LLY
    Eli Lilly and
    16 4 0
  • Is GPCR or LLY More Risky?

    Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

  • Which is a Better Dividend Stock GPCR or LLY?

    Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Structure Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios GPCR or LLY?

    Structure Therapeutics quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Structure Therapeutics's net income of -$36.5M is lower than Eli Lilly and's net income of $4.4B. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 70.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus 16.55x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GPCR
    Structure Therapeutics
    -- -- -- -$36.5M
    LLY
    Eli Lilly and
    16.55x 70.43x $13.5B $4.4B
  • Which has Higher Returns GPCR or TERN?

    Terns Pharmaceuticals has a net margin of -- compared to Structure Therapeutics's net margin of --. Structure Therapeutics's return on equity of -- beat Terns Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GPCR
    Structure Therapeutics
    -- -$0.64 --
    TERN
    Terns Pharmaceuticals
    -- -$0.28 --
  • What do Analysts Say About GPCR or TERN?

    Structure Therapeutics has a consensus price target of $80.15, signalling upside risk potential of 267.85%. On the other hand Terns Pharmaceuticals has an analysts' consensus of $19.06 which suggests that it could grow by 486.54%. Given that Terns Pharmaceuticals has higher upside potential than Structure Therapeutics, analysts believe Terns Pharmaceuticals is more attractive than Structure Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    GPCR
    Structure Therapeutics
    7 0 0
    TERN
    Terns Pharmaceuticals
    5 3 0
  • Is GPCR or TERN More Risky?

    Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Terns Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock GPCR or TERN?

    Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Structure Therapeutics pays -- of its earnings as a dividend. Terns Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GPCR or TERN?

    Structure Therapeutics quarterly revenues are --, which are smaller than Terns Pharmaceuticals quarterly revenues of --. Structure Therapeutics's net income of -$36.5M is lower than Terns Pharmaceuticals's net income of -$21.9M. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Terns Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus -- for Terns Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GPCR
    Structure Therapeutics
    -- -- -- -$36.5M
    TERN
    Terns Pharmaceuticals
    -- -- -- -$21.9M
  • Which has Higher Returns GPCR or VKTX?

    Viking Therapeutics has a net margin of -- compared to Structure Therapeutics's net margin of --. Structure Therapeutics's return on equity of -- beat Viking Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GPCR
    Structure Therapeutics
    -- -$0.64 --
    VKTX
    Viking Therapeutics
    -- -$0.32 --
  • What do Analysts Say About GPCR or VKTX?

    Structure Therapeutics has a consensus price target of $80.15, signalling upside risk potential of 267.85%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 232.87%. Given that Structure Therapeutics has higher upside potential than Viking Therapeutics, analysts believe Structure Therapeutics is more attractive than Viking Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    GPCR
    Structure Therapeutics
    7 0 0
    VKTX
    Viking Therapeutics
    9 1 0
  • Is GPCR or VKTX More Risky?

    Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.651%.

  • Which is a Better Dividend Stock GPCR or VKTX?

    Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Structure Therapeutics pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GPCR or VKTX?

    Structure Therapeutics quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Structure Therapeutics's net income of -$36.5M is lower than Viking Therapeutics's net income of -$35.4M. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GPCR
    Structure Therapeutics
    -- -- -- -$36.5M
    VKTX
    Viking Therapeutics
    -- -- -- -$35.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock